EMMA · Emmaus Life Sciences, Inc.

Emmaus Life Sciences disclosed its full-year 2025 financial results via press release on March 30, 2026, highlighting a challenging yet improved operational performance. Net revenues dropped 25% to $12.5 million from $16.7 million in 2024, primarily from reduced U.S. sales amid mid-2024 generic L-Glutamine competition, though partially mitigated by higher MENA region sales. Despite the revenue decline, the company achieved a rare operating profit of $0.2 million, reversing a $1.9 million loss, thanks to aggressive 34% cuts in operating expenses to $11.4 million through headcount reductions and other efficiencies. CEO Willis Lee emphasized the strategic pivot toward international growth potential in MENA, while announcing a U.S. license and exclusive distribution agreement with NeoImmuneTech, Inc., set for full Q2 2026 rollout to counter domestic pressures. However, other expenses surged to $7.5 million from $4.5 million, driven by $1.4 million higher loss on debt extinguishment, $1.4 million increased interest, and a $1.0 million lower gain on restructured debt, leading to a wider net loss of $7.2 million ($0.11 per share on 64.0 million shares) versus $6.5 million ($0.10 per share) prior year. Balance sheet shows modest liquidity improvement with cash at $2.1 million (up from $1.4 million), but heavy liabilities of $85.0 million dwarf assets of $21.4 million, yielding a $63.6 million stockholders' deficit. Investors should note the strategic U.S. shift and international focus as key forward drivers amid ongoing sickle cell disease treatment commercialization via Endari®.